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Abstract
There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-
resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with
docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly
assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a
diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] ¼ 17.4 to
22.1 months) and 21.2 months (95% CI¼20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio
for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI¼0.84 to 1.09),
indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have
shorter OS duration than white men treated with docetaxel.
In the United States, the age-adjusted incidence and mortality
rates for prostate cancer are much lower for Asian American
men compared with white men (1). Individuals of Asian descent
are estimated to constitute around 7% of the US population.
There are few data regarding disparities in overall outcomes
between Asian and white men with metastatic castration-
resistant prostate cancer (mCRPC). Moreover, the relative
efficacy of docetaxel in Asian men with mCRPC compared with
white men is largely unknown because of the small number of
Asian men enrolled on the pivotal studies that led to the
approval of docetaxel for this indication (2,3). To address these
limited data, we performed a pooled analysis of multiple phase
III trials in men with mCRPC treated with docetaxel, with the
goal of comparing overall survival (OS) in Asian vs white men.
We included 8820 men who participated in phase III trials of
docetaxel and prednisone (DP) vs DP plus an experimental agent
(2–11). Men enrolled in these trials between 1990 and 2014 had a
diagnosis of prostate adenocarcinoma, developed progressive
metastatic disease during androgen deprivation therapy, and,
when relevant, progressed despite antiandrogen withdrawal (2–
11).
Data on 7952 white and Asian men from nine phase III trials
were pooled, regardless of treatment arm, because these trials
comparing DP with DP plus an experimental agent had failed to
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show statistically significant differences in OS between their
arms (2–11). The main objective of this analysis was to estimate
the adjusted pooled hazard ratio (HR) for death. Two-stage fixed
effect approach was used in analyzing the data (12,13). In the
first stage, hazard ratios from each of the trials were estimated.
In the second stage, estimates from individual trials were com-
bined to obtain an overall estimate of the HR along with the var-
iance. We computed weighted average coefficients, 95%
confidence intervals (CI) for the coefficients, and Cochran Q’s
and I2 statistics for testing heterogeneity across the trials
(12,13). Within each trial, we employed the proportional hazards
model (this assumption was not verified) to adjust for age,
ECOG performance status, prostate-specific antigen, alkaline
phosphatase, hemoglobin, and sites of metastases.
The median age at diagnosis and the proportion of patients
with performance status of 0–1 were similar in Asian and white
men (Table 1). Baseline laboratory parameters predictive of OS
were slightly less favorable in Asian compared with white men
(median hemoglobin of 12.2 g/dL vs 13.0 g/dL; median alkaline
phosphatase of 150 U/L vs 138 U/L). Proportionally, more Asian
men had the liver as a site of metastases than white patients
(12.5% vs 8.4%). However, prostate-specific antigen levels were
slightly lower in Asian men: 60.1 ng/mL vs 84.9 ng/mL. The me-
dian follow-up time was 30.7 months (95% CI¼ 30.2 to 31.2
months) among surviving patients, with a total of 4969 deaths
observed (event rates of 62.7% in Asian and 62.5% in white men).
The median OS were 18.8 months (95% CI ¼ 17.4 to 22.1
months) and 21.2 months (95% CI¼20.8 to 21.7 months) for
Asian and white men, respectively (Figure 1A). However, when
adjusting for important prognostic factors, the pooled hazard
ratio for death in Asian men was 0.95 (95% CI ¼ 0.84 to 1.09;
Figure 1B) vs white men, demonstrating that Asian men had no
statistically significant differences in their risk of death.
Focusing on men who participated in the “National Cancer
Institute” National Clinical Trials Network (NCI NCTN) trials is
critical because these studies enrolled patients in the United
States, and complete information on race and ethnicity was col-
lected. When the three NCI NCTN trials were considered sepa-
rately, the median OS was shorter in Asian men (15.8 months,
95% CI¼ 11.4 to 27.6 months) than white men (20.0 months, 95%
CI¼ 19.2 to 20.9 months). In the 2022 white and 28 Asian men
who were enrolled in the NCI NCTN trials, the pooled multivari-
able hazard ratio for death for Asian vs white men was
1.24(0.81- 1.89) (See new supplementary Figure 1A, available
online). This difference might reflect true differences in out-
comes for the NCI NCTN Asian men, or simply the very small
number of Asian men accrued to the NCI NCTN trials. Thus,
caution should be exerted in interpreting the pooled hazard ra-
tio from the NCI NCTN trials.
In 4108 patients treated with DP alone, the median OS were 18.4
months (95% CI¼ 15.9 to 22.2 months) and 20.8 months (95%
CI¼ 20.1 to 21.5 months) in Asian and white patients, respectively.
In multivariable analysis, the pooled hazard ratio for death was 1.04
(95% CI¼ 0.86 to 1.24) (Supplementary Figure 1B, available online).
Several authors indicated that Asian men have less tolerance for
docetaxel, and thus their dose is often lower than the standard dose
of 75mg/m2 (14–19). In this analysis, we had no access to dosing in-
formation or limited information about toxicity and are unable to
confirm that docetaxel is poorly tolerated in the Asian population.
The main limitation of this analysis is that the patient popu-
lation was highly selected. Also, this study does not account for
heterogeneity among the population of Asian men with pros-
tate cancer, and race was not further categorized in these clini-
cal trials. It is possible that Asian men born or living in the
United States might have different characteristics and out-
comes to Asian men living in Asia.
A striking difference in terms of accrual patterns between in-
dustry and the NCI NCTN trials was observed in these trials.
Whereas the industry trials, which were mostly conducted outside
the United States, were successful in enrolling a higher proportion
of Asian patients with mCRPC (6%), the US-based NCTN trials
lagged behind and only enrolled 1% (28 patients) (Supplementary
Figure 2, available online). The proportion of Asian patients en-
rolled on the US-based NCTN trials is much lower than the esti-
mated US Asian population of about 6% and much lower than the
3.4% of Asian patients who are diagnosed with prostate cancer.
This observation has been confirmed in other analyses (20–23).
Barriers to participation of underrepresented populations in cancer
trials include clinical, structural, and attitudinal (physicians and
patients) factors and vary by demographic and socioeconomic
Table 1. Baseline characteristics of 7952 Asian and white men with mCRPC*
Baseline characteristic
Asian White Total
(n¼ 424) (n¼ 7528) (n¼ 7952)
Median age (25th, 75th percentile), y 69.0 (62.0, 73.0) 69.0 (63.0, 74.0) 69.0 (63.0, 74.0)
Performance status, % 95.2 94.5 94.5
0 50.4 44.6 44.9
1 44.8 49.9 49.6
Median PSA (25th, 75th percentile), ng/ml 60.1 (19.1, 170.0) 84.9 (30.5, 246.6) 83.5 (29.8, 243.0)
Median alkaline phosphatase (25th, 75th percentile), U/L 150.0 (91.5, 343.5) 138.0 (85.0, 284.0) 138.0 (86.0, 288.0)
Median hemoglobin (25th, 75th percentile), g/dL 12.2 (11.0, 13.4) 13.0 (11.8, 14.2) 13.0 (11.8, 14.1)
Median testosterone (25th, 75th percentile), ng/dL 15.0 (7.3, 25.0) 18.0 (10.0, 26.0) 18.0 (10.0, 26.0)
Site of metastases, %
LN only 4.5 6.7 6.6
Bone only 46.5 42.4 42.7
Bone þ LN 27.4 29.7 29.5
Lung 5.0 9.0 8.8
Liver 12.5 8.4 8.6
Other visceral 3.8 2.8 2.8
Randomized to docetaxel and prednisone arm (%) 56.6 51.7 51.7
Median follow-up time (range) 28.1 (0.0–63.8) 30.8 (0.0–94.2) 30.7 (0.0–94.2)
*LN ¼ Lymph Nodes; mCRPC ¼metastatic castration-resistant prostate cancer; PSA ¼ prostate-specific antigen.
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factors (24–26). Specific reasons for lack of participation of Asian
patients in clinical trials are largely unknown because this popula-
tion is understudied. Efforts to increase participation of Asian
patients with mCRPC in prostate cancer trials are urgently needed.
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Figure 1. (A) Kaplan—Meier overall survival (OS) curves by white and Asian patients. (B) Forest plot with hazard ratios (HR) for OS comparing Asian men with white
men (reference group ¼white men; Q=11.721, df=8, P=0.164; I2= 0.317). CI ¼ confidence interval; N ¼ number of patients; n ¼ number of deaths; NE ¼ not estimated.
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